The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumInsights - It looks like a risk associated with some approved antibiotics may not be a concern for Cempra’s (CEMP) own late-stage candidate, solithromycin. Cempra announced on … Continue Reading
Read nowInsights - Two weeks ago with the release of data from an ongoing phase 2 study of the company’s oncology candidate, PSMA ADC, shares of Progenics Pharmaceuticals (PGNX) took … Continue Reading
PremiumRecap - Incyte (INCY) has been one of PropThink’s most profitable recommendations in the last year. The stock is up nearly 190% since we first began covering the name in July of 2013. This … Continue Reading
Read nowResearch - BioDelivery Sciences (BDSI) and partner Endo Health Solutions (ENDP) announced on the 23rd that the second of three phase 3 trials testing one of its lead drug candidates, BEMA buprenorphine, … Continue Reading
Read nowResearch -  Incyte (INCY) has been one of PropThink’s most profitable recommendations in the last year, with shares rising over 187% since our July 2013 initiation of … Continue Reading
PremiumRecap - It looked briefly at mid-week like the biotech sector’s correction might be a comical 48-hour event, but investors are in a tizzy over the emerging … Continue Reading
Read nowInsights - With the release of its full-year ’13 and Q4 financials on Thursday, Alexion Pharmaceuticals (ALXN) beat on both earnings and revenue, now guiding for 2014 … Continue Reading
Read now
